<DOC>
	<DOCNO>NCT02624856</DOCNO>
	<brief_summary>The purpose study compare efficacy duration pain relief total knee arthroplasty provide single injection liposomal bupivacaine ( EXPARELÂ® ) versus standard bupivacaine adjuvant , dexamethasone administer quadriceps spar femoral nerve block periarticular injection . It hypothesize liposomal bupivacaine superior standard bupivacaine dexamethasone decrease time discharge readiness .</brief_summary>
	<brief_title>Liposomal Bupivacaine Versus Standard Bupivacaine Plus Dexamethasone Quadriceps Sparing Femoral Nerve Block Wound Infiltration Total Knee Arthroplasty</brief_title>
	<detailed_description />
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Pain , Postoperative</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Bupivacaine</mesh_term>
	<criteria>Adult patient American Society Anesthesiologist ( ASA ) IIII physical class preoperative diagnosis primary osteoarthritis schedule elective primary total knee arthroplasty . Patients must live independently home prior undergoing primary total knee arthroplasty intention discharge directly home hospitalization Subjects eligible trial history allergy local anesthetic Known peripheral neuropathy Known connective tissue immunological disorder Stroke known central nervous system disorder Renal dysfunction Hepatic dysfunction Cardiac dysfunction hypertension Pregnant subject Immunosuppression Human immunodeficiency virus ( HIV ) Alcohol drug abuse Chronic pain opioid dependence Coagulopathy unable comply study requirement .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>primary total knee arthroplasty</keyword>
	<keyword>liposomal bupivacaine</keyword>
</DOC>